October 2015, Vol. 4, No. 5 - 16th International Lung Cancer Congress
Despite the promise of molecular profiling, approximately 80% of patients with lung cancer lack a defined genotypic mutation and thus become resistant when treated with a tyrosine kinase inhibitor. According to data presented at the congress, however, lung cancer remains a highly mutated disease, suggesting great potential for immunotherapy. “If [ Read More ]
September 2014, Vol 3, No 6 - Lung Cancer
Experts discuss how they use mutational testing The expansion of tumor genetic profiling into the clinic has led to effective, targeted treatments for patients but created a daily dilemma for oncologists: What to do with the results of these tests? At the 15th Annual International Lung Cancer Congress, a panel [ Read More ]
Copyright 2023. Amplity Medical Communications. All Rights Reserved. Privacy Policy. Sitemap.
